Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

$24.99

Economic Value Added (EVA)

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

AbbVie Inc., economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


Net Operating Profit After Taxes (NOPAT)
The NOPAT experienced a significant increase between 2020 and 2021, rising from 4,455 million US dollars to 12,362 million US dollars. This was followed by a slight decline in 2022 to 11,543 million US dollars. In the subsequent years, 2023 and 2024, there was a marked reduction in NOPAT, falling to 3,292 million US dollars and then slightly recovering to 4,563 million US dollars.
Cost of Capital
The cost of capital showed a steady upward trend throughout the period analyzed. It increased from 7.84% in 2020 to 9.52% in 2024, indicating rising expense or risk associated with the company’s capital base over these years.
Invested Capital
Invested capital consistently decreased each year from 2020 to 2024. It declined from 103,725 million US dollars in 2020 to 69,263 million US dollars in 2024. This suggests a reduction in the company's overall capital investment or asset base during this period.
Economic Profit
Economic profit showed volatility across the years. It was negative in 2020 at -3,678 million US dollars, turned positive in 2021 and 2022 with 4,058 million and 3,936 million US dollars respectively, before becoming negative again in 2023 and 2024 with -3,171 million and -2,031 million US dollars. This pattern implies inconsistent value creation relative to the cost of capital.

Net Operating Profit after Taxes (NOPAT)

AbbVie Inc., NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net earnings attributable to AbbVie Inc.
Deferred income tax expense (benefit)1
Increase (decrease) in restructuring reserve2
Increase (decrease) in equity equivalents3
Interest expense
Interest expense, operating lease liability4
Adjusted interest expense
Tax benefit of interest expense5
Adjusted interest expense, after taxes6
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income7
Investment income, after taxes8
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in restructuring reserve.

3 Addition of increase (decrease) in equity equivalents to net earnings attributable to AbbVie Inc..

4 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

5 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

6 Addition of after taxes interest expense to net earnings attributable to AbbVie Inc..

7 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

8 Elimination of after taxes investment income.


The financial data reveals significant fluctuations in key profitability metrics over the five-year period from 2020 to 2024. Net earnings attributable to the company show a marked increase between 2020 and 2021, more than doubling from 4,616 million USD to 11,542 million USD. This upward trend continued slightly into 2022, reaching 11,836 million USD. However, a sharp decline is observed in 2023, where net earnings drop to 4,863 million USD, followed by a further decrease in 2024 to 4,278 million USD.

Similarly, net operating profit after taxes (NOPAT) exhibits a strong growth trajectory in the initial years, rising from 4,455 million USD in 2020 to 12,362 million USD in 2021, before slightly decreasing to 11,543 million USD in 2022. In contrast to the early upward momentum, NOPAT experiences a significant fall in 2023 to 3,292 million USD, although it recovers somewhat in 2024 to 4,563 million USD.

Net Earnings Attributable to the Company
Demonstrated substantial growth in the first two years, peaking in 2022.
Experienced a pronounced decline in the subsequent years, reaching the lowest point in 2024 within the presented timeframe.
Net Operating Profit After Taxes (NOPAT)
Followed a similar pattern to net earnings, with rapid growth through 2021, slight reduction in 2022.
Showed a sharp decline beginning in 2023, with modest recovery in 2024 albeit remaining well below earlier peak levels.

Overall, the data points toward a period of strong profitability gains up to 2022, followed by notable erosion in both net earnings and NOPAT over the last two years. The decline in profitability metrics during 2023 and 2024 suggests the presence of operational challenges or market conditions adversely impacting financial performance. The partial resurgence of NOPAT in 2024 hints at potential stabilization or early signs of financial recovery.


Cash Operating Taxes

AbbVie Inc., cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Income tax expense (benefit)
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Income Tax Expense (Benefit) Trend
The income tax expense exhibited significant volatility over the analyzed period. It began with a notable benefit of -$1,224 million at the end of 2020, indicating a tax gain or credit that reduced tax burden during that year. This reversed sharply in 2021 to a tax expense of $1,440 million, then further increased to $1,632 million in 2022. In 2023, it slightly decreased but remained high at $1,377 million. However, in 2024, the income tax expense again turned negative, showing a benefit of -$570 million. This pattern suggests fluctuating tax positions or adjustments possibly due to changes in tax regulations, earnings variations, or deferred tax accounting impacts.
Cash Operating Taxes Trend
The cash operating taxes consistently increased from 2020 through 2023, indicating increasing cash payments for taxes despite fluctuations in reported income tax expense. In 2020, cash taxes were $1,585 million, which rose significantly each year to reach $4,625 million in 2023. However, in 2024, there was a notable decline in cash operating taxes to $1,339 million, which is substantially lower than the prior years. This decline could suggest a one-time tax payment adjustment, changes in taxable income, tax credits utilization, or other operational tax strategies impacting cash outflows.
General Observations
While reported income tax expenses fluctuated between benefits and expenses, cash taxes paid showed a general increasing trend until a sharp drop in 2024. The divergence between income tax expense and cash operating taxes through the years implies differences between accounting recognition of tax expenses and actual tax payments, which is common in companies with complex tax structures. The decline in both income tax expense and cash operating taxes in 2024 may indicate significant tax planning outcomes or shifts in profitability affecting tax liabilities.

Invested Capital

AbbVie Inc., invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Short-term borrowings
Current portion of long-term debt and finance lease obligations
Long-term debt and finance lease obligations, excluding current portion
Operating lease liability1
Total reported debt & leases
Stockholders’ equity
Net deferred tax (assets) liabilities2
Restructuring reserve3
Equity equivalents4
Accumulated other comprehensive (income) loss, net of tax5
Noncontrolling interest
Adjusted stockholders’ equity
Construction in progress6
Available-for-sale investment securities7
Invested capital

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of restructuring reserve.

4 Addition of equity equivalents to stockholders’ equity.

5 Removal of accumulated other comprehensive income.

6 Subtraction of construction in progress.

7 Subtraction of available-for-sale investment securities.


The financial data over the provided periods reveal several significant trends related to debt, equity, and capital structure.

Total reported debt & leases
The total reported debt and leases exhibit a decreasing trend from 87,063 million USD at the end of 2020 to 60,286 million USD by the end of 2023, reflecting a substantial reduction in leverage over the first four years. However, in 2024, there is a noticeable increase to 68,019 million USD, indicating a reversal of the prior downward trend in debt levels.
Stockholders’ equity
Stockholders' equity initially increases from 13,076 million USD in 2020 to a peak of 17,254 million USD in 2022. Subsequently, it declines sharply to 10,360 million USD in 2023 and continues to deteriorate significantly in 2024, dropping to 3,325 million USD. This steep decrease in equity over the last two years suggests increased challenges with retained earnings or potential capital losses.
Invested capital
Invested capital shows a consistent downward trajectory, reducing from 103,725 million USD in 2020 to 68,204 million USD in 2023. Unlike other trends, invested capital appears to stabilize in 2024 with a slight increase to 69,263 million USD, signaling a possible floor or minor recovery in invested assets or operational capital use.

Overall, the data suggest a focused effort on debt reduction from 2020 to 2023 accompanied by increasing equity till 2022. However, the last two years highlight financial stress with declining equity and rising debt, raising concerns about the company’s capital structure stability and financial leverage. The decline and subsequent stabilization in invested capital corroborate a contraction phase followed by an attempt to maintain or increment operational investment.


Cost of Capital

AbbVie Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease obligations. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

AbbVie Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


Economic Profit
The economic profit exhibited significant volatility over the observed period. It started with a substantial loss of -3678 million US dollars in 2020, followed by a marked improvement into positive territory at 4058 million US dollars in 2021. This positive trend continued with a slight decline to 3936 million US dollars in 2022. However, the company's economic profit again turned negative in 2023 and 2024, with values of -3171 million and -2031 million US dollars respectively, indicating challenges in sustaining profitability during these later years.
Invested Capital
The invested capital showed a consistent declining trend from 2020 through 2023, decreasing from 103,725 million US dollars to 68,204 million US dollars. This decline suggests de-investment or asset reduction within the company over these years. In 2024, invested capital showed a slight increase to 69,263 million US dollars, indicating a potential stabilization or minor reinvestment after the previous downward trend.
Economic Spread Ratio
The economic spread ratio mirrored the fluctuations observed in economic profit. It was negative at -3.55% in 2020, improved significantly to reach positive levels of 4.23% in 2021 and further to 4.79% in 2022. However, the ratio deteriorated sharply in 2023 to -4.65%, becoming negative again, and partially recovered yet remained negative at -2.93% in 2024. These fluctuations suggest variability in the company’s return on invested capital relative to its cost, with periods of both value creation and destruction.
Overall Insights
The data reflects a period of instability characterized by an initial recovery and growth from 2020 to 2022, followed by a reversal with losses and diminished returns in 2023 and 2024. The reduction in invested capital across most of the timeline aligns with the negative economic profit and spread ratio in the latter years, possibly indicating strategic asset divestment or operational retrenchment in response to weaker profitability. The partial rebound in capital invested in the final year suggests possible repositioning efforts to restore financial performance.

Economic Profit Margin

AbbVie Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Net revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Net revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


Net Revenues
Net revenues exhibited an overall upward trend from 2020 through 2024. Starting at approximately 45.8 billion US dollars in 2020, revenues increased steadily, reaching a peak of 58.1 billion in 2022. Although there was a decline in 2023 to approximately 54.3 billion, revenues recovered somewhat by 2024 to about 56.3 billion, remaining above the 2021 level.
Economic Profit
The economic profit showed significant volatility across the period. It started with a negative value of about -3.68 billion US dollars in 2020, turned positive in 2021 and remained positive in 2022 with values near 4 billion. However, it reverted back to negative territory in 2023 and 2024, registering losses of approximately -3.17 billion and -2.03 billion respectively. This fluctuation indicates cycles of profitability followed by periods of economic loss despite generally increasing revenues.
Economic Profit Margin
The economic profit margin mirrored the pattern seen in economic profit. It was negative in 2020 at -8.03%, turning positive in the following two years to 7.22% in 2021 and 6.78% in 2022. Once again, the margin became negative in the most recent periods, registering -5.84% in 2023 and -3.61% in 2024. This suggests a decline in profitability relative to revenue despite the increase in total net revenues.
Overall Insights
The data indicates that although the company’s revenue base has generally grown over the five-year period, profitability has been inconsistent, with economic profit and its margin swinging between positive and negative values. The reversal to negative economic profit and margin in the latter two years signals potential underlying issues affecting cost management, investment returns, or other operational factors influencing economic value creation beyond just top-line growth.